Rhythm Pharmaceuticals Reports $194M in 2025 IMCIVREE Sales
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Newsfilter
- Significant Sales Growth: Rhythm Pharmaceuticals anticipates approximately $194 million in net product revenues from global sales of IMCIVREE® in 2025, representing a 50% increase from 2024, indicating strong market demand in the rare neuroendocrine disease sector.
- Quarterly Performance Boost: The estimated sales for Q4 2025 are around $57 million, reflecting an 11% increase from Q3 2025, showcasing sustained demand and patient acceptance for IMCIVREE in both U.S. and international markets.
- FDA Approval Progress: The company plans to submit a supplemental NDA for IMCIVREE for acquired hypothalamic obesity to the FDA by March 20, 2026, which, if approved, will further expand its market reach and address patient needs.
- Clinical Trial Data Release: Topline data from a 12-patient Japanese cohort in the Phase 3 trial is expected to be announced in Q1 2026, providing crucial support for the global promotion of IMCIVREE.
Analyst Views on RYTM
Wall Street analysts forecast RYTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RYTM is 140.62 USD with a low forecast of 123.00 USD and a high forecast of 167.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 105.950
Low
123.00
Averages
140.62
High
167.00
Current: 105.950
Low
123.00
Averages
140.62
High
167.00
About RYTM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
